======= MBD2 ======= == Gene Information == * **Official Symbol**: MBD2 * **Official Name**: methyl-CpG binding domain protein 2 * **Aliases and Previous Symbols**: N/A * **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=8932|8932]] * **UniProt**: [[https://www.uniprot.org/uniprot/Q9UBB5|Q9UBB5]] * **Interactions**: [[https://thebiogrid.org/search.php?search=MBD2&organism=9606|BioGRID]] * **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20MBD2|Open PubMed]] * **OMIM**: [[https://omim.org/entry/603547|Open OMIM]] == Function Summary == * **Entrez Summary**: DNA methylation is the major modification of eukaryotic genomes and plays an essential role in mammalian development. Human proteins MECP2, MBD1, MBD2, MBD3, and MBD4 comprise a family of nuclear proteins related by the presence in each of a methyl-CpG binding domain (MBD). Each of these proteins, with the exception of MBD3, is capable of binding specifically to methylated DNA. MECP2, MBD1 and MBD2 can also repress transcription from methylated gene promoters. The protein encoded by this gene may function as a mediator of the biological consequences of the methylation signal. It is also reported that the this protein functions as a demethylase to activate transcription, as DNA methylation causes gene silencing. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Feb 2011]. * **UniProt Summary**: Binds CpG islands in promoters where the DNA is methylated at position 5 of cytosine within CpG dinucleotides. Binds hemimethylated DNA as well. Recruits histone deacetylases and DNA methyltransferases. Acts as transcriptional repressor and plays a role in gene silencing. Functions as a scaffold protein, targeting GATAD2A and GATAD2B to chromatin to promote repression. May enhance the activation of some unmethylated cAMP-responsive promoters. {ECO:0000269|PubMed:10471499, ECO:0000269|PubMed:10947852, ECO:0000269|PubMed:12665568, ECO:0000269|PubMed:16415179, ECO:0000269|PubMed:24307175, ECO:0000269|PubMed:9774669}. |MBD| |satellite DNA binding| |siRNA binding| |chromatin silencing at rDNA| |parental behavior| |maternal behavior| |positive regulation of chromatin binding| |methylation-dependent chromatin silencing| |C2H2 zinc finger domain binding| |regulation of chromatin binding| |regulation of DNA methylation| |methyl-CpG binding| |heterochromatin| |reproductive behavior| |histone deacetylase complex| |nucleosomal DNA binding| |chromatin organization involved in negative regulation of transcription| |chromatin silencing| |chromatin organization involved in regulation of transcription| |ATP-dependent chromatin remodeling| |negative regulation of gene expression, epigenetic| |RNA polymerase II distal enhancer sequence-specific DNA binding| |response to estradiol| |gene silencing| |mRNA binding| |chromatin remodeling| |positive regulation of Wnt signaling pathway| |positive regulation of binding| |response to mechanical stimulus| |regulation of gene expression, epigenetic| |nuclear chromatin| |protein domain specific binding| |aging| |regulation of DNA metabolic process| |regulation of Wnt signaling pathway| |covalent chromatin modification| |regulation of binding| |embryonic organ development| |response to nutrient levels| |RNA polymerase II proximal promoter sequence-specific DNA binding| |heart development| |response to extracellular stimulus| |cellular response to organic cyclic compound| |behavior| |protein-containing complex| |chromatin organization| |multicellular organismal reproductive process| |cellular protein-containing complex assembly| |multicellular organism reproduction| |response to lipid| |negative regulation of transcription by RNA polymerase II| |circulatory system development| |response to hormone| |response to organic cyclic compound| |embryo development| |chromosome organization| |response to abiotic stimulus| |negative regulation of transcription, DNA-templated| |negative regulation of nucleic acid-templated transcription| |negative regulation of RNA biosynthetic process| |negative regulation of RNA metabolic process| |negative regulation of cellular macromolecule biosynthetic process| |reproductive process| |reproduction| |negative regulation of nucleobase-containing compound metabolic process| |negative regulation of macromolecule biosynthetic process| |response to endogenous stimulus| |negative regulation of cellular biosynthetic process| |negative regulation of biosynthetic process| |response to oxygen-containing compound| |protein-containing complex assembly| |regulation of cell population proliferation| |positive regulation of signal transduction| |negative regulation of gene expression| |positive regulation of molecular function| |positive regulation of cell communication| |positive regulation of signaling| |protein-containing complex subunit organization| \\ === CRISPR Data === ^Screen^Score^ |[[:results:exp415|Trichostatin-A 0.06μM R07 exp415]]|-2.32| |[[:results:exp498|Lead acetate 2000μM R08 exp498 no dilution day6]]|-2.09| |[[:results:exp467|CAY10603 0.55μM R08 exp467]]|-1.88| |[[:results:exp134|MS023 2μM R03 exp134]]|-1.8| |[[:results:exp349|Cytochalasin-B 5μM R07 exp349]]|-1.77| |[[:results:exp417|Tubastatin-A 2.5μM R07 exp417]]|-1.76| |[[:results:exp6|Bortezomib 0.005μM R00 exp6]]|-1.74| |[[:results:exp463|Caffeine 2600μM R08 exp463]]|-1.74| |[[:results:exp374|Latrunculin-B 10μM R07 exp374]]|-1.74| |[[:results:exp66|BI-D1870 3.15μM R02 exp66]]|1.8| |[[:results:exp500|LY2090314 0.003μM R08 exp500 no dilution day6]]|1.82| |[[:results:exp321|ABT-702 5μM plus Deferoxamine 11μM R07 exp321]]|1.97| |[[:results:exp350|Deferoxamine 11μM R07 exp350]]|2.23| |[[:results:exp326|CCT251545 20μM R07 exp326]]|2.24| |[[:results:exp95|BI-2536 0.0042μM R03 exp95]]|2.26| |[[:results:exp290|LLY-283 2.6μM R06 exp290]]|2.28| |[[:results:exp89|Vemurafenib 6.6μM R02 exp89]]|3.74| |[[:results:exp434|Vemurafenib 6.6μM R08 exp434]]|4.39| ^Gene^Correlation^ |[[:human genes:h:hdac1|HDAC1]]|0.413| Global Fraction of Cell Lines Where Essential: 1/726 ^Tissue^Fraction Of Cell Lines Where Essential^ |1290807.0|0/1| |909776.0|0/1| |bile duct|0/28| |blood|0/28| |bone|0/25| |breast|0/33| |central nervous system|0/56| |cervix|0/4| |colorectal|0/17| |esophagus|0/13| |fibroblast|0/1| |gastric|0/15| |kidney|0/21| |liver|0/20| |lung|0/75| |lymphocyte|0/14| |ovary|0/26| |pancreas|0/24| |peripheral nervous system|0/16| |plasma cell|1/15| |prostate|0/1| |skin|0/24| |soft tissue|0/7| |thyroid|0/2| |upper aerodigestive|0/22| |urinary tract|0/29| |uterus|0/5| == Essentiality in NALM6 == * **Essentiality Rank**: 7368 * **Expression level (log2 read counts)**: 6.46 {{:chemogenomics:nalm6 dist.png?nolink |}}